




Cordlife Group Limited

FY2024 Annual General Meeting

10 June 2025



Disclaimer


This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract or commitment whatsoever in this or any jurisdiction. This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on these forward-looking statements, if any, which are based on the current view of management on future events. The information contained in this presentation has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Neither Cordlife or any of its affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. The past performance of Cordlife is not indicative future performance. The value of shares in Cordlife (“Shares”) and the income derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by, Cordlife or any of its affiliates. An investment in Shares is subject to investment risks, including the possible loss of the principal amount invested.

Agenda

- 1 **Status of Ongoing Enhancements**
- 2 **Resumption of Singapore Operations**
- 3 **FY2024 Financial Summary**
- 4 **Outlook**

- Advanced lab monitoring system implemented
- Critical equipment further backed by multiple uninterruptible power supplies
- Enhanced SOPs, training, facility and technical staff
- Partially resume operations from 15 Sept 2024

Cordlife's business reset may give shareholders the best chance to ba



公司也已同受事件影响的顾客取得联系

Cordlife has also reduced the cost of its price plans by 20 to 25 per cent since resuming its services in a limited manner on Sep 15.



Media Tour of Yishun Facility on 17 Sept 2024



Cordlife resumes services after facilities, operations overhaul

Salma Khalik
Senior Health Correspondent

Cordlife resumed its cord blood banking services on Sept 15 after a hiatus of 9½ months, during which it overhauled its facilities and operations to meet the standards required by the Ministry of Health (MOH).

The green light it has received from the ministry comes with caveats, including being allowed to receive no more than 30 new cord blood units (CBUs) a month for the first six months. This is less than 10 per cent of the roughly 400 units a month that it used to get.

The majority of parents sign up to bank their babies' cord blood in the third trimester of pregnancy, so it will likely be a month or so before Cordlife starts receiving new CBUs when the babies are born.

MOH shut down the firm's oper-

ations on Nov 30, 2023, after finding that seven of its 22 storage tanks had been exposed to temperatures above minus 150 deg C, which could result in damage to the stem cells in the cord blood, making them non-viable.

Cord blood contains stem cells that may be used to treat blood diseases and some cancers, such as leukaemia and lymphoma, should the baby develop these illnesses later in life.

Of the 35 units withdrawn from the ministry comes with caveats, including being allowed to receive no more than 30 new cord blood units (CBUs) a month for the first six months. This is less than 10 per cent of the roughly 400 units a month that it used to get.

The majority of parents sign up to bank their babies' cord blood in the third trimester of pregnancy, so it will likely be a month or so before Cordlife starts receiving new CBUs when the babies are born.

MOH shut down the firm's oper-

06

2024年9月16日 星期二 综合 新加坡

改进运作方式
康盛脐带血储存设施添实验室监测系统



康盛实验室配有处理脐带血的自动化平台AXP系统。



康盛人生的脐带血储存设施添了新的实验室监测系统，提升其工艺标准并提升脐带血的质和量。

康盛人生集团被令暂停提供脐带血服务约九个月，上星期六（9月15日）获准有限重启业务，集团需满足参议院脐带血存储设施，介绍已落实的调整和改进措施。

康盛人生集团已于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

康盛人生集团于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

康盛人生：有充裕资金支撑长期运营

康盛人生集团（Cordlife）在暂停服务约九个月后，上星期六（9月15日）获准有限重启业务，集团需满足参议院脐带血存储设施，介绍已落实的调整和改进措施。

康盛人生集团已于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

康盛人生集团已于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

康盛人生集团已于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

康盛人生集团已于去年11月30日，在设施和操作方式，包括设立新的实验室监测系统，增加操作人员，以及加强相关设施。

Full Resumption of Operations – First Stage of Recovery

- Cord blood, tissue banking license renewed on 14 January 2025
- Granted approval for full resumption of operations
- Licences and lifting of restrictions were granted after stringent MOH audits
- Cordlife remains committed to restoring client trust and rebuilding momentum



Best News Website or Mobile Service • WAN-IFRA Digital Media Awards Worldwide 2022

Sign In My Feed Search Edition: Asia

Singapore

Cordlife's cord blood, human tissue banking service licences renewed



A Cordlife



Cordlife notes that at the current stage, it is unable to assess the impact on its fiscal performance for the financial year ending Dec 31, 2025. PHOTO: BT FILE

MOH to monitor Cordlife's governance, practices over one-year period

By Megan Cheah
megancheah@sph.com.sg

THE Ministry of Health (MOH) will closely monitor Cordlife Group's governance and ensure its practices are consistent and compliant with regulatory requirements, the ministry said on Wednesday (Jan 15).

This was in response to queries on Tuesday's statement that Cordlife's cord-blood banking service and human-tissue banking service licences have been renewed for a year, with immediate effect.

Following the announcement, the company's shares surged 10.3 per cent or \$50.015 to \$50.16, as at 3.05 pm on Wednesday. They closed later at \$50.159, up \$50.014 or 9.7 per cent.

MOH said that its audits showed that Cordlife has satisfactorily addressed critical shortcomings in various areas. This includes temperature monitoring practices, cord-blood inventory management, and incident response, said the health ministry.

Cordlife's cord-blood banking

service and human-tissue banking service licences were therefore renewed by the director-general of health.


However, in view of the recent organisational changes to Cordlife's key office holders, the licence renewal will be for a "limited period" of one year, pointed out MOH.

Cordlife on Tuesday said: "The company is committed to meeting all applicable regulatory requirements and compliance measures, before considering the full resumption of operations in Singapore."

The company added that at the current stage, it is unable to assess the impact on its fiscal performance for the financial year ending Dec 31, 2025.

Prior to this licence renewal, MOH allowed the company to resume its cord-blood banking service operations "in a controlled manner", restricting its operations to not more than 30 units per month of new cord blood from infant donors, from Sep 15, 2024, to Jan 13, 2025.

What's Next – Our Commitment to Customers



FY2024 Financial Summary (Group)

REVENUE

S\$27.6 million

(50.4)% y-o-y

GROSS PROFIT

S\$11.5 million

(69.1)% y-o-y

GP MARGIN

41.7%

(25.2) pp y-o-y

NET LOSS

S\$(18.9) million

FY2023 – S\$3.6 million

OPERATING NET (LOSS)/PROFIT MARGIN

(74.7)%

FY2023 – 3.7%

NET CASH₁


S\$67.2 million

(S\$15.3)m from 31 Dec 2023


1: Includes cash and cash equivalents, fixed deposits, short-term investments less interest-bearing borrowings (current and non-current)

Financial Highlights (Group)


FY2024 Revenue



FY2024 Gross Profit



FY2024 Percentage of Revenue (%)



¹ Revenue for Singapore was negative due to the revenue reversal arising from the Refund/Waiver for High-Risk Tanks

Outlook

We have emerged a
stronger, safer,
Cordlife

Stepped up
marketing efforts to
maintain strong
sales pipeline

Strengthened
relationships with
medical community

Engaging AABB and
FACT to restore SG
accreditations

Continuously
improve all our
facilities to sharpen
competitive edge

**Thank
you**

